Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 科学研究和技术服务业
Company Introduction 成都先导药物开发股份有限公司（上海证券交易所股票代码：688222.SH，股票名称：成都先导）致力于打造全球一流的创新型生物医药企业，总部位于中国成都，在英国剑桥、美国休斯顿设有子公司。公司聚焦小分子及核酸新药的发现与优化，着力打造了国际领先的DNA编码化合物库技术（包括DEL库的设计、合成和筛选及拓展应用）平台，并拓展了基于分子片段和三维结构信息的药物设计技术（FBDD/SBDD）、寡聚核酸新药研发相关技术（STO）和靶向蛋白降解相关技术（TPD）的核心技术平台。通过新药研发服务、不同阶段在研项目转让以及远期的药物上市等多元化的商业模式，成都先导与全球数百家制药公司、生物技术公司、化学公司、基金会以及科研机构建立了合作。目前，公司有多个内部新药项目处于临床及临床前不同阶段。
Main Business DEL技术相关的药物早期发现研发服务
Legal Representative JIN LI（李进）
Top Executives
董事长：JIN LI（李进）
副董事长：陆恺
董事：李建国,王霖,SUIBO LI,王剑明
独立董事：余海宗,郭云沛,薛军福
Top 5 Shareholder
Shareholder name Nature Holding Date
JINLI（李进）流通A股20.43%31/03/2024
拉萨经济技术开发区华博医疗器械有限公司流通A股12.70%31/03/2024
宁波聚智先导生物科技合伙企业（有限合伙）流通A股9.65%31/03/2024
安吉东方佳钰企业管理合伙企业（有限合伙）流通A股6.20%31/03/2024
深圳市钧天投资企业（有限合伙）流通A股3.52%31/03/2024
Company Secretary 耿世伟
Solicitors 北京市君合律师事务所
Auditors 德勤华永会计师事务所（特殊普通合伙）
Tel No 0028-85197385
Fax No 0028-83310298
Website www.hitgen.com
Email investors@hitgen.com
Company Address
Register: 四川省成都高新区科园南路88号1栋3层
Office: 四川省成都天府国际生物城（双流区生物城中路二段18号）
Listing Date 16/04/2020
Shares Capital
Shares Capital: 400,680,000
Total A Share: 400,680,000
Listed A Share: 400,680,000
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.100
DPS(RMB)* ¥ 0.050
NBV Per Share(RMB)* ¥ 3.390
Market Capitalization(RMB) 5.225B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.